Benjamin Brigham

Benjamin Brigham has a work experience spanning over a decade. Benjamin started their career in 2012 as a Research Associate at Alnylam Pharmaceuticals, where they focused on developing and characterizing lipid nanoparticles for siRNA therapy delivery. In this role, they also worked on platform optimization and CMC assays for Patisiran. From 2020 to 2021, Benjamin worked at Kronos Bio, Inc. as a Research Scientist, where they designed and performed biophysical and biochemical assays and conducted compound screenings. In 2022, they moved on to NextRNA Therapeutics and later to Atavistik Bio, both as a Scientist II specializing in Biophysics.

Benjamin Brigham completed their education with a Bachelor of Science degree in Biology from Boston College, where they studied from 2008 to 2012. Following this, they pursued their higher education at Tufts University School of Medicine from 2015 to 2019 and earned a Doctor of Philosophy degree in Biochemistry, Biophysics, and Molecular Biology.